Form 4: Collegium Pharmaceutical Executive Sells Shares Under 10b5-1 Trading Plan

Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold 2,255 shares of common stock at an average price of $30.0049 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 14, 2025, Scott Dreyer, the EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold 2,255 shares of the company's common stock.
• The sale was executed at a weighted average price of $30.0049 per share.
• The transactions occurred within a price range of $30.00 to $30.01.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following the transaction, Dreyer directly owns 124,421 shares of Collegium Pharmaceutical.
• Colleen Tupper, as Attorney-In-Fact, signed the Form 4 on March 18, 2025.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by executives are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sales were pre-planned and not based on any inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates